Introduction
Owkin is a Paris-founded TechBio company established in 2016 that applies federated learning and agentic artificial intelligence to drug discovery and development. Thomas Clozel, MD, co-founded Owkin with Gilles Wainrib, PhD, combining clinical oncology experience with machine-learning research, per Owkin’s about page. The company describes its mission as unlocking insights from decentralized hospital data without centralizing sensitive patient records — a privacy architecture that differentiated Owkin early in pharma AI partnerships.
On June 5, 2026, Owkin announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma AI agents backed by a five-year K Pro license — extending a partnership that began in 2021 with oncology target identification.
Owkin markets Biological Artificial Superintelligence as its long-term thesis — language that signals ambition beyond single-task ML models toward autonomous research systems vetted by Sanofi and AstraZeneca enterprise deployments.
What the company does
Owkin builds K Pro, marketed as an AI scientist for pharmaceutical research: agentic systems that orchestrate biological reasoning models, literature intelligence, and multimodal patient data to support discovery and development decisions. Owkin also operates federated data networks linking hospitals and research centers, enabling model training across institutions while keeping data local. Diagnostic products such as MSIntuit CRC and RlapsRisk BC appear in Owkin materials alongside the K Pro platform.
K Pro orchestrates skills and tools across the pharmaceutical value chain from early discovery through clinical development, per Owkin’s June 2026 Sanofi release — a scope broader than single-task ML models trained on one dataset snapshot.
Who it serves
Owkin serves large pharmaceutical companies — Sanofi, AstraZeneca, and Bristol Myers Squibb appear in Owkin news releases — plus hospital systems joining its patient data network, including NHS Lothian per a March 2026 partnership announcement on Owkin’s news center. Buyers are R&D leaders seeking faster target validation, trial enrichment, and competitive intelligence rather than hospital IT departments buying ambient scribes.
Diagnostic products MSIntuit CRC and RlapsRisk BC serve pathology and oncology workflows complementary to K Pro’s discovery agents — dual revenue lines Owkin maintains alongside pharma platform licensing.
Company background
Clozel and Wainrib founded Owkin in Paris in 2016 after concluding that complex biology requires patient-scale data plus AI, not human review alone. Owkin became a unicorn through investments from Sanofi, BMS, and venture firms per its FAQ materials. The company maintains offices in Paris, New York, London, Boston, and other cities listed on its about page. Clozel continues as chief executive officer at review time.
Owkin’s 2021 Sanofi strategic alliance began with oncology target identification and later expanded to immunology drug positioning — a multi-year relationship that matured into the June 2026 agentic AI collaboration rather than ending after initial targets were delivered.
Product and AI capabilities
Owkin’s agentic AI stack — K Pro — deploys specialized biological agents for tasks such as target identification, drug positioning, pathology exploration, and literature synthesis. Federated learning lets models train across hospital silos with privacy controls, addressing a structural barrier in oncology and immunology datasets. The June 2026 Sanofi deal positions these agents as intelligent assistants performing complex R&D tasks autonomously within Sanofi workflows, not static analytics reports.
Owkin’s January 2026 announcement of a pathology explorer agent launching with Anthropic’s Claude for healthcare and life sciences shows how Owkin combines proprietary biological models with frontier LLM infrastructure — a layered architecture pharma IT teams must security-review before production deployment.
Key developments
2016: Owkin founded in Paris by Thomas Clozel and Gilles Wainrib. November 2021: Sanofi equity investment and strategic alliance announced (background to 2026 expansion). June 5, 2026: Multi-year Sanofi K Pro agent collaboration announced. May 13, 2026: AstraZeneca K Pro license agreement announced. March 2026: NHS Lothian patient data network partnership per Owkin news center. Owkin co-founded by clinical oncologist and ML pioneer per about-us.
Why it matters
Owkin matters because pharmaceutical AI is shifting from dashboards to agentic systems that execute multi-step research tasks. Sanofi’s five-year K Pro license is a structured commercial signal — not a pilot MOU — that Owkin’s agents are entering production R&D workflows. Readers can contrast Owkin’s federated hospital network model with Komodo Health‘s de-identified claims map or Recursion‘s automated phenotypic screening labs.
Thomas Clozel’s clinical background — former assistant professor in onco-hematology per Owkin FAQs — differentiates Owkin from pure software vendors lacking physician founders who understand trial feasibility constraints.
Sector context
Owkin belongs in Brel’s AI in healthcare coverage under AI drug discovery and TechBio, alongside Recursion Pharmaceuticals, Insilico Medicine, and Exscientia. Healthcare analytics peers such as Komodo Health address complementary real-world-data problems for commercial and medical affairs teams.
Owkin’s May 2026 AstraZeneca K Pro license and June 2026 Sanofi agent collaboration show multiple top-20 pharmas licensing the same agentic platform — a concentration signal for buyers evaluating single-vendor dependency in R&D AI stacks.
Reviewed 2026-07-10.
Sources and references
Owkin Sanofi K Pro press release (June 5, 2026) and about-us page.
- Owkin — Sanofi K Pro collaboration (owkin.com, June 5, 2026)
- Owkin — About Us (owkin.com)
Reviewed July 10, 2026. Thomas Clozel, MD, is co-founder and CEO per about-us. Founded 2016 in Paris. Confidence: High. Sector: Healthcare AI biotechnology.